Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.

ABSTRACT: Polymyxin B (PMB) has reemerged as a last-line therapy for infections caused by multidrug-resistant gram-negative pathogens, but dosing is challenging because of its narrow therapeutic window and pharmacokinetic (PK) variability. Population PK (POPPK) models based on suitably powered clinical studies with appropriate sampling strategies that take variability into consideration can inform PMB dosing to maximize efficacy and minimize toxicity and resistance. Here we reviewed published PMB POPPK models and evaluated them using an external validation data set (EVD) of patients who are critically ill and enrolled in an ongoing clinical study to assess their utility. Seven published POPPK models were employed using the reported model equations, parameter values, covariate relationships, interpat

SUBMITTER: Hanafin PO 

PROVIDER: S-EPMC8674003 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature